These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27895328)

  • 1. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
    Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E
    Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328
    [No Abstract]   [Full Text] [Related]  

  • 2. European regulatory experience with drugs for central nervous system disorders.
    Butlen-Ducuing F; Zienowicz M; Pétavy F; Haas M; Salmonson T; Eichler HG; Rasi G
    Nat Rev Drug Discov; 2015 Feb; 14(2):89-90. PubMed ID: 25524018
    [No Abstract]   [Full Text] [Related]  

  • 3. Structural modifications that alter the P-glycoprotein efflux properties of compounds.
    Hitchcock SA
    J Med Chem; 2012 Jun; 55(11):4877-95. PubMed ID: 22506484
    [No Abstract]   [Full Text] [Related]  

  • 4. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory watch: Impact of scientific advice from the European Medicines Agency.
    Hofer MP; Jakobsson C; Zafiropoulos N; Vamvakas S; Vetter T; Regnstrom J; Hemmings RJ
    Nat Rev Drug Discov; 2015 May; 14(5):302-3. PubMed ID: 25881970
    [No Abstract]   [Full Text] [Related]  

  • 6. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 7. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
    Bishop KM
    Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two decades of new drug development for central nervous system disorders.
    Kesselheim AS; Hwang TJ; Franklin JM
    Nat Rev Drug Discov; 2015 Dec; 14(12):815-6. PubMed ID: 26585536
    [No Abstract]   [Full Text] [Related]  

  • 11. For the European Medicines Agency, a decade of challenges.
    Rice M
    J Natl Cancer Inst; 2005 Oct; 97(19):1403-5. PubMed ID: 16204689
    [No Abstract]   [Full Text] [Related]  

  • 12. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of predictive models in CNS diseases.
    Gomeni R
    Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Chinese medicines on cAMP/PKA signaling in central nervous system dysfunction.
    Li L; Fan X; Zhang XT; Yue SQ; Sun ZY; Zhu JQ; Zhang JH; Gao XM; Zhang H
    Brain Res Bull; 2017 Jun; 132():109-117. PubMed ID: 28438669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Medicines Agency Perspective on Oncology Study Design for Marketing Authorization and Beyond.
    Jonsson B; Martinalbo J; Pignatti F
    Clin Pharmacol Ther; 2017 May; 101(5):577-579. PubMed ID: 28073148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational research in central nervous system drug discovery.
    Hurko O; Ryan JL
    NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and cost of new drugs acting on the central nervous system.
    Garattini S; Bertele' V
    Eur J Clin Pharmacol; 2003 May; 59(1):79-84. PubMed ID: 12743674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.